Changes in invasive pneumococcal disease among HIV-infected adults living in the era of childhood pneumococcal immunization

被引:119
作者
Flannery, B [1 ]
Heffernan, RT [1 ]
Harrison, LH [1 ]
Ray, SM [1 ]
Reingold, AL [1 ]
Hadler, J [1 ]
Schaffner, W [1 ]
Lynfield, R [1 ]
Thomas, AR [1 ]
Li, JM [1 ]
Campsmith, M [1 ]
Whitney, CG [1 ]
Schuchat, A [1 ]
机构
[1] Ctr Dis Control & Prevent, Resp Dis Branch, Div Bacterial & Mycot Dis, Atlanta, GA 30333 USA
关键词
D O I
10.7326/0003-4819-144-1-200601030-00004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Adults infected with HIV have high rates of invasive pneumococcal disease. Introduction of pneumococcal conjugate vaccine for children could affect disease among HIV-infected adults. Objective: To compare invasive pneumococcal disease among HIV-infected adults before and after the introduction of a pediatric conjugate vaccine. Design: Active laboratory-based surveillance in an adult population of 10.8 million, including 38 314 living with AIDS. Setting: 7 Active Bacterial Core surveillance areas in the United States. Patients: All surveillance-area residents 18 to 64 years of age with Streptococcus pneumoniae isolated from a sterile site between 1998 and 2003. Measurements: Ratio of the number of cases of invasive pneumococcal disease among HIV-infected adults to the estimated number of adults 18 to 64 years of age living with AIDS; serotype-specific subset analyses; and comparison of periods before and after introduction of conjugate vaccine by using exact tests. Results: Of 8582 cases of invasive pneumococcal disease in adults, 2013 (24%) occurred among persons infected with HIV. Between baseline (1998 to 1999) and 2003, the ratio of invasive pneumococcal disease in HIV-infected adults to the number of adults living with AIDS in the surveillance areas decreased from 1127 to 919 cases per 100000 AIDS population, a reduction of 19% (P= 0.002). Among HIV-infected adults, the ratio for disease caused by pneumococcal serotypes included in the conjugate vaccine decreased 62% (P < 0.001), although the ratio for disease caused by nonvaccine serotypes increased 44% (P < 0.001). Limitations: Ratios are proxy measures of incidence rates. The denominator of surveillance-area residents living with HIV infection was not available. Conclusions: Introduction of the pediatric conjugate vaccine was associated with an overall decrease in invasive pneumococcal disease among HIV-infected adults, despite increased disease caused by nonvaccine serotypes.
引用
收藏
页码:1 / 9
页数:9
相关论文
共 26 条
[1]  
[Anonymous], 1992, MMWR Recomm Rep, V41, P1
[2]  
[Anonymous], 2000, MMWR Recomm Rep, V49, P1
[3]   Bacteremia among children admitted to a rural hospital in Kenya [J].
Berkley, JA ;
Lowe, BS ;
Mwangi, I ;
Williams, T ;
Bauni, E ;
Mwarumba, S ;
Ngetsa, C ;
Slack, MPE ;
Njenga, S ;
Hart, CA ;
Maitland, K ;
English, M ;
Marsh, K ;
Scott, JAG .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (01) :39-47
[4]   Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine [J].
Black, SB ;
Shinefield, HR ;
Hansen, J ;
Elvin, L ;
Laufer, D ;
Malinoski, F .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2001, 20 (12) :1105-1107
[5]   Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients [J].
Breiman, RF ;
Keller, DW ;
Phelan, MA ;
Sniadack, DH ;
Stephens, DS ;
Rimland, D ;
Farley, MM ;
Schuchat, A ;
Reingold, AL .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (17) :2633-2638
[6]  
*CDCP\, NAT IMM SURV
[7]  
*CDCP, 2004, HIV AIDS SURV REP 20, V15
[8]   Effect of the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae in the first 2 years of life [J].
Ghaffar, F ;
Barton, T ;
Lozano, J ;
Muniz, LS ;
Hicks, P ;
Gan, V ;
Ahmad, N ;
McCracken, GH .
CLINICAL INFECTIOUS DISEASES, 2004, 39 (07) :930-938
[9]  
Green TA, 1998, STAT MED, V17, P143, DOI 10.1002/(SICI)1097-0258(19980130)17:2&lt
[10]  
143::AID-SIM757&gt